Going beyond the conventional: Exploring innovative deal structures

The landscape of deal structures in the biotech industry is evolving, with stakeholders exploring innovative approaches to deal-making and asset licensing. What novel deal structures have emerged in the past few years for licensing early-stage assets to big pharma companies? How do deal structures vary based on the area of technology or therapeutic indication, and what factors influence their adoption? How do alternative payment mechanisms, such as milestone payments, royalties, and revenue-sharing arrangements, impact deal negotiations and valuation? What are the advantages and challenges of joint ventures or subsidiary programmes? What considerations should biotech companies or TTOs take into account when exploring innovative deal structures with pharma? What will be the future big pharma’s asset selection process?